The main aim of this paper was to compare results of Genescan and real-time PCR methods in order to detect contamination in harvests from patients with follicular lymphoma. The secondary goal was to evaluate the efficacy of Rituximab as an in vivo purging agent. A total of 23 patients had been treated with CHOP followed by either high-dose therapy (12 patients) or high-dose plus Rituximab (11 patients), both followed by autologous transplantation. Results show that 86% of harvests from patients treated whith Rituximab were PCR-negative compared to 14.3% from controls. Real-time PCR was more sensitive than Genescan PCR; quantitative analysis revealed a correlation between the amount of contamination in the harvests and relapse after transplantation. Whereas all patients reinfused with negative aphereses achieved complete remission and showed a significantly better 5-year PFS (100%) compared to those reinfused with contaminated samples (41%), a very low amount of contamination does not appear to negatively affect outcome, suggesting that determination of a cutoff in the contamination level of harvests could be useful. Results suggest that real-time PCR is superior to Genescan PCR to select transplantable harvests and confirm the ability of Rituximab as an in vivo purging tool for follicular lymphoma.
ma; autologous transplantation; rituximab; purging Although indolent non-Hodgkin's lymphoma (NHL) patients have a fairly long survival, they frequently experience relapses and truly curative treatments are not available to date. The most efficacious recent protocols involve high-dose therapy and anti-CD20 monoclonal antibody (Rituximab) . 1 This provides some advantages, at least in terms of halting disease progression. 2 Owing to the long median survival of patients with indolent diseases, definitive clinical results of new trials may not become evident for a long period of time. Consequently, surrogate end points of survival, such as clearance of neoplastic cells from bone marrow or peripheral blood, could be provisionally considered. In the great majority of follicular lymphoma patients, the neoplastic clone is characterized by a reciprocal balanced chromosomal translocation, the t(14;18) (q32;q21), involving the bcl2 gene on chromosome 18 and the immunoglobulin heavy chain gene on chromosome 14. 3 Highly sensitive molecular methods for detecting the t(14;18) have been developed in an attempt to clarify the possible clinical role of minimal residual disease. After a program of high-dose therapy and autotransplantation, up to 68% of patients provided uncontaminated harvests. Indeed, those patients receiving PCR-negative stem cells maintained both negative molecular status and continuous clinical remission. 4 Nevertheless, these data derive from a labor-intensive and time-consuming molecular method consisting of conventional PCR assays followed by hybridization with patient-specific radiolabeled probes. Conversely, fluorescent PCR with capillary electrophoresis (Genescan PCR) offers good sensitivity and specificity; it is a rapid and safe molecular assay, and may offer semiquantitative evaluation.
However, Genescan PCR confirms the same disadvantages already observed in other methods based on endpoint amplification analysis. To address and solve these methodological limits, this paper describes a real-time PCR-based approach which allows effective, accurate and reproducible quantitative measurement of BCL2/JH rearranged copies in stem cell harvests. This method involves the amplification of an internal standard gene (b2-microglobulin) in order to normalize samples for DNA quality and quantity. Moreover, we compared the sensitivity and informative properties of quantitative (real-time) PCR with those of a conventional (Genescan) PCR method by evaluating residual tumor burden in 36 harvests from 23 patients with follicular lymphoma. All patients were treated on third-generation protocols followed by peripheral blood stem cell (PBSC) mobilization and transplant. With the aim of evaluating the in vivo purging efficacy of Rituximab, this monoclonal antibody was added before mobilization and harvesting. Patients were included in the two groups essentially on the basis of the drug's availability. Although both methods are able to detect neoplastic contamination in harvests, results suggest a further clinical relevance of quantitative tests. Moreover, we confirm the successful clearance of PCR-detectable neoplastic cells by administration of Rituximab.
Materials and methods

Patient population
A total of 23 patients from the GISL (Gruppo Italiano Studio Linfomi) were enrolled in this study. Inclusion criteria were diagnosis of follicular lymphoma according to the REAL classification, and age 18-65 years; all included patients were proved to be IgH or BCL2/JH-positive in samples from bone marrow or lymph node biopsy at diagnosis. Other criteria were no more than three previous lines of chemotherapy; life expectancy 46 months; absence of renal, hepatic and respiratory failure; white blood cell (WBC) count 42 Â 10 9 /l, platelets (PLT) 4100 Â 10 9 /L; ECOG performance status 0-2; written informed consent. Reactivity to anti-CD20 monoclonal antibody was always tested.
Clinical characteristics of patients with follicular lymphoma are summarized in Table 1 .
In all, 17 men and six women, median age 52 years (range 29-64 years), were enrolled in the study; 61% of patients had bone marrow involvement; 12 cases had low-risk disease (IPI 0-1), 10 IPI 2 and 1 IPI 3. A total of 15 patients started CHOP/high-dose (HD) therapy as first-line strategy, whereas eight patients were enrolled after occurrence of disease progression or relapse. All but two relapsed patients had previously been treated with CHOP or CHOPlike protocols at least 1 year before. The remaining two patients had been previously treated by fludarabine-based protocols.
Patients were included in the Rituximab group (R-HD) according to the availability of the anti-CD20 antibody. All patients received anthracycline-containing regimens as firstline therapy; 15 were consolidated with high-dose therapy. 5 The remaining eight patients received a second-line therapy; they were mobilized with CTX (4-7 g/m 2 ) and were transplanted with BEAM as the conditioning regimen. In 11 patients, Rituximab was administered 1 week before CTX and 2 days before harvesting. Two additional doses followed the transplant after 4 and 5 weeks, respectively.
Complete remission (CR) was defined as the complete disappearance of all clinically detectable disease and/or reduction of lymph nodes to less than 1 Â 1 cm in size visible on CT scan. Partial remission (PR) was defined as a greater than 50% reduction in diameter for measurable lesions; progressive disease (PD) was considered to be an increase in size of more than 25% of previously documented disease, or the appearance of disease at any site.
Statistical analyses
All calculations were performed using the SPSS for Windows, release 10.1, 2001. Time to relapse or progression was analyzed by the Kaplan-Meier method. Difference in PFS between prognostic groups was evaluated on univariate analysis by the log-rank test. Comparisons of clinical response data by individual prognostic variables were performed using the w 2 test.
Molecular assays
Genescan PCR. Bone marrow samples taken at the onset of therapy and harvested stem cells were isolated by fractionation on Ficoll/Hypaque gradient; high molecular weight DNA was extracted and suitable aliquots were utilized for PCR tests after spectrophotometrical quantitative evaluation. In order to amplify BCL2/JH rearrangement, nested PCR reactions were performed in a final volume of 25 ml by using 1 mg of DNA, 0.4 mmol/l of oligonucleotide primers, 200 mmol/L each of dNTPs, MgCl 2 2 mM and 1.5 U Taq polymerase (Eurobio, Les Ulis, France) in the 1X PCR buffer (67 mmol/l Tris-HCl, pH 8.8, 16 mmol/l (NH 4 ) 2 SO 4 , 0.01% Tween 20).
The first round of PCR was performed for 25 cycles and the second round for 30 cycles; primers for MBR and reaction conditions have been previously described by Gribben et al.,
1 employing an inner JH primer 6-FAM labeled. A non-Hodgkin's lymphoma cell line with t(14;18), the OCI-LY8 cell line, was employed as positive control of reaction. 6 Amplification product length never exceeded 300 bp.
PCR-amplified products were resolved by both 2.5% agarose gel and capillary electrophoresis. Samples were prepared for analysis on DNA sequencer by mixing 1 ml of PCR products with 15 ml of deionized formamide (Sigma, St Louis, MO, USA) and 0.5 ml Genescan t500 Tamralabeled internal standard (Applied Biosystem, Warrington, UK). This mixture was denatured at 951C for 2 min and then quickly cooled on ice. Capillary electrophoresis and fluorescence detection with a virtual C filter were performed Clinical parameters of patients are reported according to treatment group: HD: patients treated by high dose chemotherapy; R-HD: patients treated by high-dose chemotherapy plus Rituximab (see text). The only relevant difference between two groups concerns the number of patients over 50.
on an ABI Prism 310 Genetic Analyzer (Applied Biosystem, Warrington, UK). Runs were executed with the module GS STR POP 4 (1 ml) C with 10 s and 15 kV injection and run voltage, 601C constant temperature, 24 min running time, using polymer POP 4 and the running buffer Genetic Analyser 1X (Applied Biosystem).
Genescan 2.1 software was then used to analyze the PCR products, with accurate sizing and quantification of the peak areas.
Quantitative real-time PCR. For detection of the MBR/ JH fusion product, we utilized an oligonucleotide primer flanking the MBR and a consensus oligonucleotide primer complementary to the IgH joining region.
PCR amplification was also performed under identical conditions with primers specific to the human b2Àmicroglobulin to confirm the amplifiability and quantity of the DNA sample.
Reaction mixture contained QuantiTec SYBR Green PCR Master Mix (Qiagen, Hilden, Germany) and 0.4 pmol/ ml primers.
The following PCR protocol was used for amplification and detection using Sybr Green: after 2 min at 501C to allow the destruction by UNG of potential contaminant PCR products, and 15 min at 951C to activate Hot StarTaq DNA polymerase. Amplification was carried out for 60 cycles: denaturation at 951C for 30 s, annealing at 581C for 30 s and elongation at 721C for 30 s.
As described above, real-time PCR reactions were performed by employing Sybr Green I dye: as it is a fluorescent intercalating dye, it detects all dsDNA, including primer dimers and other undesired products. In order to test the specificity of the assay, a melting profile was performed. When the fluorescence is monitored continuously throughout a temperature cycle, product denaturation can be observed as a rapid loss of fluorescence near denaturation temperature. As the melting curve of a product is dependent on its GC content, length and sequence, PCR products can be distinguished by their melting curves. Melting profiles in positive samples always showed a unique patient-specific peak, whereas a specific amplification was detectable by observing several rounded peaks, with lower melting temperatures. 7 Quantification was performed by standard curve established with serial dilutions (2500, 250, 25, 0.25) of OCY-LY8 cell line DNA. These dilutions were prepared at the same time for all tests and conserved at 41C. Samples were analyzed in parallel with the standard under identical conditions. The BCL2/JH copy and b2-microglobulin copy number was calculated by interpolation from the standard curve.
Results
Qualitative analysis of bone marrow samples before harvesting
After progressive logarithmic dilutions of the rearranged OCY-LY8 cell line, the Genescan PCR molecular method was able to detect a minimum of 25 DNA copies (Figure 1) .
Qualitative analyses on bone marrow samples obtained at the beginning of the study were performed by Genescan PCR technique. BCL2/JH rearrangement was detected in roughly half of the patients (12/23) before either first-or second-line therapy. Advanced stages of disease and bone marrow involvement were significantly related to the molecular status (P ¼ 0.01 and 0.005 respectively, by Pearsons w 2 test).
Qualitative PCR analysis of harvests
Concerning molecular status at the beginning of the study, no significant differences were found between the two groups. Seven patients were PCR-positive in the R-HD and five in the HD group. Groups were balanced in terms of sex, IPI and pretreatment. Conversely, older patients were more frequently found in the R-HD group. Since age is a negative prognostic factor, this difference does not appear to have been a bias for our study. In all, 36 harvests from the 23 patients were tested initially by the qualitative molecular method, and contaminated precursors were harvested from 15 patients (65.2%) (Figure 2 ). Bone marrow molecular contamination at the onset of the study significantly correlated with the contamination of leukapheresis products evaluated by Genescan technique (P ¼ 0.005). No qualitative differences between consecutive aphereses were noted. In total, 11 of the 12 cases with PCR-positive bone marrow at the onset mobilized contaminated harvests. On the other hand, 7/11 cases with PCR-negative bone marrow harvested PCRnegative samples. It is noteworthy that none of the remaining four cases belonged to the R-HD group. Conversely, only one patient, who mobilized molecularly uncontaminated stem cells starting from a PCR-positive bone marrow, was in the Rituximab cohort. Altogether, the PCR-negative harvests were more frequently found in the R-HD group (P ¼ 0.005) (Table 2a) .
Real-time PCR quantitative analysis
Real-time PCR sensitivity tests, performed by diluting OCI-Ly8 cell line 6 with cells from a healthy donor, showed that 2.5 BCL2/JH rearranged DNA copies were already detectable ( Figure 3 ).
However, evaluation of DNA from non-lymphoid cell lines (MCF-7, HL-60, OCI-AML5) and from nine healthy donors previously revealed to be PCR-negative by standard methods, showed a very late fluorescence related to a possible aspecific reaction. It is easily differentiable from the specific fluorescence found by evaluating BCL2/JH rearranged cell lines by an accurate melting curve analysis. Thus, to avoid overestimation of positive results, real-time was computed as positive when the number of BCL2/JH copies was greater than 258, corresponding to the mean plus two s.d.'s of values found in healthy donors. However, the lowest number of DNA copies found in positive samples was 808.
By adopting these criteria, 12 of 19 tested leukapheresis products (63.2%) tested positive by real-time PCR. A significant correlation between qualitative Genescan and quantitative real-time results was found (P ¼ 0.01). Discordance was found in only four cases. In fact, two harvests which resulted negative by Genescan were positive according to real-time method, while two additional cases, positive at the qualitative analysis, were negative according to the quantitative method. As previously observed using qualitative PCR assays, real-time PCR analysis showed that percentage of contaminated harvests was significantly lower in the group of patients receiving Rituximab, with 60% of negative products harvested in the R-HD compared to 11% in the HD group (P ¼ 0.027). The number of BCL2/JH copies detected in the R-HD group ranged from 2138 to 3018 (mean 1095.5) and did not differ significantly from those found in the HD group (range 808-2084; mean 5915) (Table 2B ). Harvests from patients entering this protocol after a first-line therapy showed a significantly higher rate of contamination (P ¼ 0.01). The absolute number of BCL2/JH rearranged copies proved to be independent from bone marrow involvement or basal molecular status, but it significantly correlated with the administration of Rituximab.
Clinical outcome
Seven patients (five in the control arm and two in the Rituximab group) refused transplant and were not considered for clinical evaluation. In all, 11 of 16 patients achieved CR, with an overall response rate of 68.8%. Two patients remained stable and three progressed during treatment or follow-up. In this study, none of the prognostic variables usually evaluated for clinical response (ie sex, stage, bone marrow involvement, IPI, number of previous therapies) showed a significant impact on clinical outcome. Clinical response was not influenced by qualitative bone marrow molecular status as determined at the beginning of the study. Conversely, PCR negativity of PBSC evaluated by Genescan method correlated with CR rate. All six patients receiving PCR-negative precursors achieved CR; conversely, only 5/10 cases harvesting contaminated aphereses achieved the complete clinical remission (P ¼ 0.037).
With a median follow-up of 41 months, two patients (one in each cohort) died because of disease progression, with a 5-year OS of 87.5%. Six of the 16 evaluated patients (37.5%) progressed; the estimated 5-year PFS was 57.3%. Sex, age, stage, bone marrow involvement, IPI, pretreatment and clinical response did not influence survival time.
On the contrary, PCR positivity in bone marrow samples at the onset of therapy was significantly associated with shorter PFS, with 5-year PFS of 38% in PCR-positive vs 72% in the PCR-negative group (P ¼ 0.04). OS was not significantly different between patients transplanted with apheretics PCR-positive or -negative products when harvests were evaluated by both qualitative and quantitative molecular techniques. Conversely, no relapses occurred in cases reinfused with PCR-negative products, compared to six relapses observed in patients transplanted with contaminated aphereses (P ¼ 0.03). In spite of the absence of a statistical significance after Kaplan-Meier analysis, PFS was better for patients reinfused with PCR-negative harvests (5-year PFS 100 vs 41%) (Figure 4) . Focusing on patients transplanted with contaminated harvests, a significantly shorter PFS was found in patients receiving harvests with the highest (42886 copies) contamination levels (P ¼ 0.008).
Discussion
This study was designed to assess the possible role of different contamination levels of stem cell harvests on the outcome of patients with follicular lymphoma, evaluated by two different PCR methods: Genescan PCR and real-time PCR. The secondary aim was to investigate whether the addition of Rituximab to HD therapy could induce a complete eradication of BCL2/JH-positive cells.
In spite of the long natural history of indolent lymphomas, 66.4% patients relapse, with 5-year OS of 45%, in agreement with the results from the GELF 86 study. 8 This trial showed better OS rates for patients receiving high-dose instead of conventional therapy (58 vs 38% at 5 years, respectively). In the present study, HD therapy appears to be unaffected by the more frequently employed prognostic factors, while only molecular analyses retained prognostic significance. Several studies have confirmed the advantage of administrating Rituximab to patients with follicular lymphoma at the time of diagnosis or at relapse. Rituximab effectiveness has been shown to be increased by aIFN activity, allowing 42% of molecular remissions even in relapsed patients. 9 Moreover, the association of Rituximab and CHOP was advantageous even from the molecular point of view, with 70% of molecular remissions. 10 If the role of HD therapy and autologous transplantation appears to be promising in indolent NHL, 11 the clinical relevance of the presence of contaminating tumor cells in harvests and detectable minimal residual disease is still a matter for debate.
Several authors 12 have shown longer DFS after in vitro purging of leukapheresis products. Nevertheless, the ex vivo techniques for purging are often labor-intensive, may delay bone marrow recovery, and are quite expensive. Moreover, several concerns arise from the implications of T-cell depletion in the control of residual disease and infectious complications which should be considered when CD34-positive purging is performed. On the contrary, the in vivo purging by monoclonal antibodies is able to reduce the amount of contaminating tumor cells, by several logs, without adversely affecting the number and quality of harvested stem and accessory cells, associated with an improvement in clinical outcome.
Magni et al 13 clearly showed that harvests from patients treated with Rituximab and mobilized by CTX and ARA-C were PCR negative in 93% of cases, compared with 40% of patients treated according to the same protocol but without monoclonal antibody.
The adverse prognostic role of contaminated leukaphereses was shown by Moos et al;
14 30% of a series of 52 patients engrafted with contaminated precursors relapsed whereas no patients relapsed in the group receiving PCRnegative stem cells.
In order to detect MRD in harvest products, Genescan PCR was initially adopted. This molecular assay is rapid, quite sensitive, specific and allowed us to follow the patientspecific PCR product already characterized at the onset of malignancy. By associating the limiting dilution method to the Genescan PCR, semiquantitative results may be achieved. Nevertheless, the analysis at the end of reaction and the manipulation of samples after amplification are intrinsic disadvantages. These problems may be overcome by using real-time PCR. Using this technique, laboratory contamination is minimized, since the fluorescent signal is measured in closed tubes. Moreover, the threshold Cycle (Ct) is observed during the exponential phase, thus avoiding the intrinsic limitations of end-point reaction analysis. Finally, by using a standard curve, real-time PCR tests give absolute quantitative results. The Sybr Green method was chosen for two reasons: (i) the breakpoints on the JH gene in follicular lymphomas are often variable, (ii) employment of a fluorescent dye with the same conditions as those adopted in the Genescan procedure could allow a better comparison of the two methods. Nevertheless, the Sybr Green method requires an accurate interpretation of the melting curve, in order to avoid ambiguous interpretations.
In our study, Genescan sensitivity results were one log lower than that achieved by real-time PCR assays.
Both molecular techniques employed showed that administration of Rituximab can significantly reduce the harvest contamination rate. In total, 86% of harvests from patients who received the monoclonal antibody were PCR negative compared to 14.3% of patients treated without Rituximab. The infusion of uncontaminated harvests seems to improve clinical results. In fact, a low contamination level is associated with a late or possibly absent relapse, whereas transplantation of highly contaminated PBSC is frequently followed by disease progression. This finding appears to have several implications: first, the strict dependence of the patient's outcome on the quality of PBSC transplanted suggests that, unlike other diseases (ie, multiple myeloma), the conditioning regimen used in this malignancy may be able to eradicate the disease. Second, a low number of reinfused neoplastic cells may not be able to support the follicular lymphoma reconstitution, or at least did not during our short follow-up period. Third, on the basis of these results, it appears to be unnecessary to discharge all contaminated aphereses; however, it is reasonable to utilize those with the lowest contamination levels.
Conversely, patients who recovered highly contaminated PBSC should be assigned to different therapeutic protocols. Finally, quantitative real-time PCR detection of BCL2/JH rearranged cells in precursor harvests appears to be not only more sensitive but also more informative than qualitative analysis.
We are now searching for a cutoff level to determine the allowable number of neoplastic cells in leukapheresis which may be safely transplanted in follicular lymphoma patients.
